Panacea Global (HOML) 10-Q 13 Aug 14 2014 Q2 Quarterly report Financial data

Document_and_Entity_Informatio

Document and Entity Information	6 Months Ended
	Jun. 30, 2014
Document and Entity Information:	'
Entity Registrant Name	'PANACEA GLOBAL, INC.
Document Type	'10-Q
Document Period End Date	30-Jun-14
Amendment Flag	'false
Entity Central Index Key	'0001024048
Current Fiscal Year End Date	'--12-31
Entity Common Stock, Shares Outstanding	105,997,586
Entity Filer Category	'Smaller Reporting Company
Entity Current Reporting Status	'Yes
Entity Voluntary Filers	'No
Entity Well-known Seasoned Issuer	'No
Document Fiscal Year Focus	'2014
Document Fiscal Period Focus	'Q2

Panacea_Global_Inc_Balance_She

Panacea Global, Inc. - Balance Sheets (USD $)	Jun. 30, 2014		Dec. 31, 2013
Current Assets:	'		'
Cash	$152,184		$2,309,563
Other Assets, current	199,498		49,040
TOTAL CURRENT ASSETS	351,682		2,358,603
Investment, current	909,992	[1]	911,672	[1]
Property and equipment, net	82,511	[2]	78,236	[2]
Intangible asset, net	50,000,000	[3]	50,000,000	[3]
Total Non-Current Assets	50,992,503		50,989,908
Total Assets	51,344,185		53,348,511
LIABILITIES	'		'
Accounts payable and accrued liabilities, current	369,103		390,074
Due to related parties, current	540,810	[4]	720,209	[4]
Deferred revenue, current	1,000,000	[1]	1,000,000	[1]
License fee payable, current	'	[1]	574,211	[1]
TOTAL LIABILITIES	1,909,913		2,684,494
Stockholders' Equity	'		'
Preferred Stock	0	[5]	0	[5]
Capital Stock	105,998	[6]	105,998	[6]
Additional paid-in capital	55,948,583		55,145,783
Deficit accumulated during the development stage	-6,649,972		-4,720,970
Accumulated other comprehensive (income) loss	29,663		133,206
Total Stockholders' Equity	49,434,272		50,664,017
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	$51,344,185		$53,348,511
[1]	See Note 5
[2]	See Note 9
[3]	See Note 6
[4]	See Note 11
[5]	$0.001 par value; 100,000 shares authorized, none issued; See Note 7
[6]	$0.001 par value; 300,000,000 shares authorized; 105,997,586 issued and outstanding (December 31, 2013- 105,997,586); See Note 7

Statement_of_Financial_Positio

Statement of Financial Position - Parenthetical (USD $)	Jun. 30, 2014	Dec. 31, 2013
Statement of Financial Position	'	'
Common Stock, Par Value	$0.00	$0.00
Common Stock, Shares Authorized	300,000,000	300,000,000
Common Stock, Shares Issued	105,997,586	105,997,586
Common Stock, Shares Outstanding	105,997,586	105,997,586
Preferred Stock, Par Value	$0.00	$0.00
Preferred Stock, Shares Authorized	100,000	100,000
Preferred Stock, Shares Issued	0	0
Preferred Stock, Shares Outstanding	0	0

Panacea_Global_Inc_Statements_

Panacea Global, Inc. - Statements of Operations (USD $)	3 Months Ended				6 Months Ended				53 Months Ended
	Jun. 30, 2014		Jun. 30, 2013		Jun. 30, 2014		Jun. 30, 2013		Jun. 30, 2014
Income Statement	'		'		'		'		'
Revenue	'		'		'		'		'
EXPENSES	'		'		'		'		'
Professional fees	103,220		72,094		134,731		103,020		885,773
Cost of reorganization	'		'		'		'		39,300
Filing Fees	2,308		2,039		4,322		4,340		39,697
Office and General	432,982		193,839		750,493		305,045		2,621,900
Depreciation	3,774		4,859		8,736		9,349		46,236
Stock based compensation	802,800		'		802,800		'		1,927,167
Salaries and benefits	122,675		69,704		226,240		88,133		882,240
TOTAL EXPENSES	1,467,759		342,535		1,927,322		509,887		6,442,313
Equity income/ (loss) pickup	-1,472	[1]	5,696	[1]	-1,680	[1]	5,646	[1]	-90,008	[1]
Net loss before income taxes	-1,469,231		-336,839		-1,929,002		-504,241		-6,532,321
Tax expense	'		'		'		'		-117,651
Net Loss	-1,469,231		-336,839		-1,929,002		-504,241		-6,649,972
Foreign currency adjustment	-24,325		6,249		-103,543		20,653		29,663
Comprehensive Loss	($1,493,556)		($330,590)		($2,032,545)		($483,588)		($6,620,309)
Net loss per share-basic and diluted	($0.01)		$0		($0.02)		($0.01)		($0.07)
Weighted number of shares outstanding- basic and diluted	105,997,586		98,133,872		105,997,586		97,551,962		90,372,511
[1]	See Note 5

Panacea_Global_Inc_Statements_1

Panacea Global, Inc. - Statements of Cash Flows (USD $)	6 Months Ended				53 Months Ended
	Jun. 30, 2014		Jun. 30, 2013		Jun. 30, 2014
Cash flows from Operating Activities	'		'		'
Net Loss	($1,929,002)		($504,241)		($6,649,972)
Adjustments to reconcile net loss to net cash used in operating activities:	'		'		'
Loss (income) pickup on Joint Venture	1,680	[1]	-5,646	[1]	90,008	[1]
Depreciation	8,736		9,349		46,236
Stock based compensation	802,800		'		1,927,167
Stock issued for services	'		'		59,300
Total Income (Loss)	-1,115,786		-500,538		-4,527,261
Change in assets and liabilities:	'		'		'
Other Assets	-150,458		-7,856		-199,498
Accounts payable and accrued liabilities, increase decrease	-20,971		-76,594		369,103
Deferred revenue, increase decrease	'		'		1,000,000
License fee payable, increase decrease	-574,211		-323,444		-2,500,000
Net cash used in operating activities	-1,861,426		-908,432		-5,857,656
Cash Flows from Investing Activities	'		'		'
Undistributed loss on joint venture	'	[1]	'	[1]	-1,000,000	[1]
Purchases of property and equipment	-13,011		-14,619		-128,747
Net cash used in investing activities	-13,011		-14,619		-1,128,747
Cash Flows From Financing Activities	'		'		'
Issuance of common stock	'		1,279,088		6,568,114
Due to related parties, increase decrease	-179,399		-174,146		540,810
Net cash provided by financing activities	-179,399		1,104,942		7,108,924
Effect of exchange rate on cash	-103,543		20,653		29,663
Net change in cash	-2,157,379		202,544		152,184
Cash, Beginning of Year	2,309,563		109,151		'
Cash, End of Year	152,184		311,695		152,184
Supplemental Disclosures of Cash Flow Information:	'		'		'
Interest paid	'		'		'
Taxes paid	'		'		'
[1]	See Note 5

Nature_of_Operations_and_Organ

Nature of Operations and Organization	6 Months Ended
	Jun. 30, 2014
Notes	'
Nature of Operations and Organization	'
	1.                 NATURE OF OPERATIONS AND ORGANIZATION
	MoneyLogix Group, Inc. ("MoneyLogix" or the “Company”), which registered a change of name with the State of Nevada on January 29, 2008, was formerly known as Homelife, Inc. and is organized under the laws of the State of Nevada.
	MoneyLogix Group, Inc. entered into a share exchange agreement which closed on June 30, 2010 with Panacea Global, Inc. (“Panacea”), a Delaware private corporation incorporated on February 5, 2010. The reverse merger transaction effected a change of control of the Company. The accounting acquirer is Panacea and the historical operations of the Company are the operations of Panacea.  Pursuant to the terms of the share exchange agreement, MoneyLogix agreed to issue 74,800,000 shares of its common stock to the stockholders of Panacea Global, Inc. in exchange for 100% of Panacea’s issued and outstanding stock, making Panacea a wholly owned subsidiary of the Company on June 30, 2010.
	The Company is a development stage company that has currently acquired the global rights except for the United States of America for early detection cancer tests.
	Effective June 2, 2011, MoneyLogix Group, Inc. registered a change of name with the State of Nevada to Panacea
	Global, Inc. Effective June 15, 2011, the trading symbol for the Company on the OTC Bulletin Board changed from "MLXG" to “PANG”.

Basis_of_Presentation

Basis of Presentation	6 Months Ended
	Jun. 30, 2014
Notes	'
Basis of Presentation	'
	2.                 BASIS OF PRESENTATION
	The Company has not earned any revenues from limited principal operations and accordingly, the Company's activities have been accounted for as those of a "Development Stage Enterprise" as set forth in Accounting Standard Codification (“ASC”) 915 Accounting and Reporting by Development Stage Enterprises.  Among the disclosures required by ASC 915 are that the Company's consolidated financial statements be identified as those of a development stage company, and that the consolidated statements of operations, stockholders' deficit and cash flows disclose activity since the date of the Company's inception.

Going_Concern

Going Concern	6 Months Ended
	Jun. 30, 2014
Notes	'
Going Concern	'
	3.                 GOING CONCERN
	These unaudited interim condensed consolidated financial statements have been prepared assuming the Company will continue on a going-concern basis. The Company incurred losses since inception and the ability of the Company to continue as a going-concern depends upon its ability to raise additional finance to fund its operations and develop profitable operations. Accumulated net losses from inception to June 30, 2014 totaled $6,649,972.  In order for the Company to meet its liabilities as they come due and to continue its operations, the Company is solely dependent upon its ability to generate such financing. There is no assurance that the Company will be able to obtain such financing. These conditions create material uncertainty that cast significant doubt about the Company’s ability to continue as a going concern.

Summary_of_Significant_Account

Summary of Significant Accounting Policies	6 Months Ended
	Jun. 30, 2014
Notes	'
Summary of Significant Accounting Policies	'
	4.                 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
	The accounting policies of the Company are in accordance with accounting principles generally accepted in the United States. Presented below are those policies considered particularly significant:
	Basis of Consolidation and Presentation
	The accompanying interim condensed consolidated financial statements include the accounts of the Company, and its wholly-owned subsidiary Panacea (a Delaware incorporated Company) and Panacea Global Inc. (a Canadian incorporated Company).  All inter-company transactions and balances have been eliminated upon consolidation.
	The interim condensed consolidated financial statements of the Company included herein have been prepared by the Company, without audit, pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”). Certain information and footnote disclosures normally included in financial statements prepared in conjunction with accounting principles generally accepted in the United States have been condensed or omitted pursuant to such rules and regulations, although the Company believes that the disclosures are adequate to make the information presented not misleading. These interim condensed consolidated financial statements should be read in conjunction with the Company’s 2013 year end annual consolidated audited financial statements and the notes thereto included in the Company’s annual report on Form 10-K.
	The accompanying interim condensed consolidated financial statements reflect all adjustments of a normal and recurring nature which are, in the opinion of management, necessary to present fairly the financial position, results of operations and cash flows of the Company for the interim periods presented. The results of operations for these periods are not necessarily comparable to, or indicative of, results of any other interim period or for the fiscal year taken as a whole. Certain information that is not required for interim financial reporting purposes has been omitted.
	Translation of Foreign Currency Financial Statements and Foreign Currency Transactions
	The functional currency of the Company is Canadian dollars. The functional currency of the Company’s subsidiaries is United States dollars.  The interim condensed financial statements of the Company have been translated into United States dollars by translating balance sheet accounts at year end and period end exchange rates except for non-current assets which are translated at historical exchange rates, and statement of operations accounts at average exchange rates for the periods. Foreign currency translation gains and losses are reflected in the equity section of the Company’s consolidated balance sheet in Accumulated Other Comprehensive Income (Loss). The balance of the foreign currency translation adjustment, included in Accumulated Other Comprehensive Loss, was $ (103,543) for the six months ended June 30, 2014. For the period from inception (February 5, 2010) through June 30, 2014, $29,663 foreign currency translation adjustment was included in Accumulated Other Comprehensive Income (Loss).
	Earnings or Loss Per Share
	The Company accounts for earnings per share pursuant to ASC 260-10-05, Earnings per Share, which requires disclosure on the financial statements of "basic" and "diluted" earnings (loss) per share. Basic earnings (loss) per share are computed by dividing net income (loss) by the weighted average number of common stock outstanding for the period. Diluted earnings (loss) per share is computed by dividing net income (loss) by the weighted average number of common stock outstanding plus common stock equivalents (if dilutive) related to stock options and warrants for each period.  In periods of losses, diluted loss per share is computed on the same basis as basic loss per share as the inclusion of any other potential shares outstanding would be anti-dilutive.
	Financial Instruments
	In accordance with ASC 825-10-50, Defining Fair Value Measurement, the estimated fair value of financial instruments has been determined by the Company using available market information and valuation methodologies. Considerable judgment is required in estimating fair value. Accordingly, the estimates may not be indicative of the amounts the Company could realize in a current market exchange. As of June 30, 2014, the carrying value of accounts payable and accrued liabilities, due to related parties and license fee payable approximate their fair value because of the short-term maturity of these instruments.  The fair value of the investment is not readily determinable.
	In accordance with ASC 820-10, Defining Fair Value Measurement, the Company adopted the standard which defines fair value, establishes a framework for measuring fair value in generally accepted accounting principles and expands disclosures about fair value measurements.
	Income Taxes
	The Company accounts for income taxes pursuant to ASC 740-10, Accounting for Income Taxes. Deferred tax assets and liabilities are recorded for differences between the financial statements and tax basis of the assets and liabilities as well as loss carry forward that will result in taxable or deductible amounts in the future based on enacted tax laws and rates. Valuation allowances are established when necessary to reduce deferred tax assets to the amount expected to be realized. Income tax expense is recorded for the amount of income tax payable or refundable for the period increased or decreased by the change in deferred tax assets and liabilities during the period.
	Impairment of Long-lived Assets
	In accordance with ASC 360-10-05, Accounting for the Impairment or Disposal of Long-Lived Assets, long-lived assets to be held and used are analyzed for impairment whenever events or changes in circumstances indicate that the related carrying amounts may not be recoverable. The Company evaluates whether events and circumstances have occurred that indicate possible impairment. If there are indications of impairment, the Company uses future undiscounted cash flows of the related asset or asset grouping over the remaining life in measuring whether the assets are recoverable. In the event such cash flows are not expected to be sufficient to recover the recorded asset values, the assets are written down to their estimated fair value. Long-lived assets to be disposed of are reported at the lower of carrying amount or fair value of asset less cost to sell. The Company evaluated the Global Diagnostic License on June 30, 2014 and noted no impairment.
	Use of Estimates
	The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. These estimates are reviewed periodically, and, as adjustments become necessary, they are reported in earnings in the period in which they become known. The accounting estimates that require management’s most significant judgments are the valuation of the intangible asset and measurement of accrued liabilities.
	Cash and Cash Equivalents
	For the purposes of the balance sheets and statement of cash flows, cash and cash equivalents include deposits, certificates of deposit and all highly liquid debt instruments with original maturities of three months or less.  The Company maintains cash and cash equivalents at financial institutions which periodically may exceed federally insured limits.
	Property and Equipment
	Property and equipment are initially recorded at cost.  Depreciation is provided using the declining balance method at rates intended to amortize the cost of assets over their estimated useful lives.
		Method	Rate
	Computer equipment	Declining balance	30%
	Furniture and equipment	Declining balance	20%
	Lab equipment	Declining balance	30%
	Leasehold improvements	Declining balance	20%
	In the year of acquisition, depreciation is taken as assets are available for use.
	Equity Compensation
	The Company adopted ASC 718, Share-Based Payment, which establishes standards for transactions in which an entity exchanges its equity instruments for goods and services. This standard focuses primarily on accounting for transactions in which an entity obtains employee services in share-based payment transactions, including issuance of stock options to employees. The Company measures stock-based compensation cost at grant date, based on the estimated fair value of the award, and recognizes the cost as expense on a straight-line basis (net of estimated forfeitures) over the employee requisite service period. The Company estimates the fair value of stock options using a Black-Scholes valuation model.
	Investment in Equity Instruments
	The Company has accounted for its investment in equity and debt securities using the equity method of accounting based on the guidelines established in FASB ASC 323. In applying the guidance of FASB ASC 323, the Company recognizes the investment in stock of an investee as an asset. The asset is recorded initially at cost in accordance with the guidance in FASB ASC 805-50-30. Subsequent to the initial recording the Company will recognize its share of the earnings or losses of an investee in the periods for which they are reported by the investee in its financial statements. The Company adjusts the carrying value of the investment for its share of the earnings or losses of the investee after the date of investment and shall report the recognized earnings or losses in the condensed statement of comprehensive loss.
	Recent Accounting Pronouncements
	Changes to accounting principles generally accepted in the United States of America (U.S. GAAP) are established by the Financial Accounting Standards Board (FASB) in the form of accounting standards updates (ASU’s) to the FASB’s Accounting Standards Codification.
	The Company has assessed the applicability and impact of all ASU’S and they have been determined to be either not applicable or are expected to have minimal impact on the Company’s condensed consolidated financial position and statements of operations.

Global_Diagnostic_License

Global Diagnostic License	6 Months Ended
	Jun. 30, 2014
Notes	'
Global Diagnostic License	'
	5.                GLOBAL DIAGNOSTIC LICENSE
	License Agreement
	On March 24, 2010, the Company entered into a license agreement with Panacea Pharmaceuticals Inc. (“Pharmaceuticals”) to acquire the global diagnostic license (“GDL”), with rights to sublicense worldwide, except for the United States of America.  GDL allows the Company to develop, market and use licensed products related to HAAH based laboratory tests.
	In consideration for the GDL, the Company issued 35,500,000 common shares and will pay Pharmaceuticals a license fee of $2,500,000, due within 30 days of the Company raising a minimum $10,000,000 equity investment.  One-half of any equity investments raised shall be remitted to Pharmaceuticals, until the license fee is paid in full. The aggregate consideration paid and therefore fair value of the GDL equates $50,000,000.  Further, the Company will pay Pharmaceuticals 25% of all sublicensing revenue and will purchase all conforming reagent at a cost of $20 per test or 10% of the sale price of the individual test with a minimum $8.00 test price.
	As at December 31, 2011, the Company engaged a third party professional valuation firm to review the license agreement and determine an appropriate representation of fair value of the intangible asset. The valuation report considered current conditions of the Company and industry as well as projections of future performance based on management’s judgment of the likelihood of future outcomes. Results of the valuation report indicated that the intangible asset was not impaired as of December 31, 2011.  As at June 30, 2014, management is of the opinion that there has been no change to those circumstances.
	The Company made license fee payments of $2,220 during the three months ended June 30, 2014 and $64,976 for the six months ended June 30, 2014 ($323,444 during the six months ended June 30, 2013). At June 30, 2014, the Company has made aggregate license fee payments of $639,187 to reduce the license fee payable from $574,211 as of December 31, 2013 to $0, and have a balance receivable of $64,976 as of June 30, 2014 included in other assets.
	Sublicense Agreement
	On November 18, 2011, the Company entered into a sublicense agreement with Panacea Laboratories, Inc. (“Laboratories”) to sublicense the rights to develop, market and use licensed products related to HAAH based laboratory tests in Canada.
	In consideration for the rights received under the sublicense agreement, Laboratories provided the Company with 40,000,000 shares of its common stock and will pay the Company a sublicense fee of $960,000, due within 3 years.  The fair value of the aggregate consideration paid and therefore the initial cost of the investment equated to $1,000,000, which was recognized as the initial asset balance of the investment.  Further, Laboratories must purchase all conforming reagents from the Company at a cost of $20 per test or 10% of the sale price of the individual test with a minimum $8.00 test price.
	Sublicensing revenues of $1,000,000 had been recorded in deferred revenues as at December 31, 2011 and will be taken into revenues once Laboratories commences operations. The amount of deferred revenues is unchanged since year-end. Upon the recognition of revenue, the Company will recognize its liability to reimburse Panacea Pharmaceuticals 25% of all sublicensing revenue as disclosed above in under the terms of the license agreement.
	Based on the accounting guidance of FASB ASC 323, the Company’s investment in Laboratories was subsequently decreased due to the Company’s share of the losses in Laboratories’ operations. The Company’s investment of 40,000,000 common shares represents a 50% ownership interest in Laboratories. Laboratories intends to raise capital in the current year through issuing additional shares and the Company’s ownership interest in Laboratories is expected to decline.  The Company has significant influence over Laboratories but does not have the level of control that would require consolidation and has thus accounted for its investment in Laboratories using the equity method.
	Investment in Laboratories
	November 18, 2011 (initial value)	$	1,000,000
	Share of losses up to December 31, 2013		-88,328
	31-Dec-13		911,672
	Share of loss for the six months ended June 30, 2014		-1,680
	Total	$	909,992
	The investment in Laboratories was $909,992 and $911,672 as of June 30, 2014 and December 31, 2013 respectfully.  The reduction in the investment during the 6 months ended June 30, 2014 represents the Company’s share of the operating expenses incurred at laboratories.

Intangible_Asset

Intangible Asset	6 Months Ended
	Jun. 30, 2014
Notes	'
Intangible Asset	'
	6.                INTANGIBLE ASSET
	The Company’s intangible asset consists of the GDL, as described in Note 5, which contains certain issued and pending patent rights. Upon commencement of licensed services to customers, amortization will be taken over the estimated useful life of the respective patent rights, which vary and are determined on a country-by-country basis.
		As at February 5, 2010 (inception)	Acquired	Accumulated Amortization	As at December 31, 2013	Accumulated Amortization	As at
							30-Jun-14
	Global Diagnostic License	-	$50,000,000	-	$50,000,000	-	$50,000,000
	As at June 30, 2014, the Company has not commenced any services relating to GDL and as a result, no amortization has been recorded.

Capital_Stock

Capital Stock	6 Months Ended
	Jun. 30, 2014
Notes	'
Capital Stock	'
	7.                CAPITAL STOCK
	a)       Authorized
	100,000 Class A Preferred shares with a par value of $0.001. There were no shares issued and outstanding at June 30, 2014.
	300,000,000 Common shares of $0.001 par value.
	b)       Issued
	105,997,586 Common Shares (105,997,586 Common Shares – December 31 2013).
	Common Shares
	On April 5, 2012, the Company issued an additional 500,000 common shares for cash of $121,652.
	On August 17, 2012, the Company issued an additional 100,000 common shares for cash of $49,985.
	On September 17, 2012, the Company issued an additional 280,000 common shares for cash of $139,477.
	On September 25, 2012, the Company issued an additional 320,000 common shares for cash of $160,000.
	On October 12, 2012, the Company issued an additional 100,000 common shares for cash of $50,000.
	On March 1, 2013, the Company issued an additional 40,000 common shares for services valued at $20,000.
	On April 29, 2013, the Company issued an additional 1,184,000 common shares for cash of $592,000.
	On May 31, 2013, the Company issued an additional 860,000 common shares for cash of $380,000.
	On June 4, 2013, the Company issued an additional 20,000 common shares for cash of $10,000.
	On July 8, 2013, the Company issued an additional 680,000 common shares for cash of $287,105.
	On July 26, 2013, the Company issued an additional 100,000 common shares for cash of $50,000.
	On August 13, 2013, the Company issued an additional 100,000 common shares for cash of $50,000.
	On December 4, 2013, the Company issued an additional 50,000 common shares for cash of $25,000.
	On December 31, 2013, the Company issued an additional 6,000,000 common shares for cash of $3,000,000.
	Warrants
	On February 25, 2013, the Company issued an additional 1,600,000 common shares for cash of $352,895.
			Number of Shares	Capital Stock	Additional
					paid in capital
	Capital stock as at December 31, 2011		94,063,586	94,064	49,869,603
	Stock issuances in 2012		1,300,000	1,300	519,814
	Capital stock as at December 31, 2012		95,363,586	$95,364	$50,389,417
	Stock issuance in 2013		10,634,000	10,634	4,756,366
	Capital stock as at December 31, 2013		105,997,586	$105,998	$55,145,783
	Stock based compensation in 2014		-	-	802,800
	Capital stock as at June 30, 2014		105,997,586	$105,998	$55,948,583
	The following table provides consolidated information on the Company’s warrants for as at June 30, 2014.  Each warrant provides the warrant holder the option to purchase one share.
		Number of  Warrants	Exercise Price	Exercisable Date	Expiry Date
	Warrants issued on April 10, 2011	2,000,000	$0.25	Anytime	10-Apr-13
	Warrants issued on April 15, 2011	100,000	$0.25	Anytime	15-Apr-13
	Warrants issued on April 5, 2012	500,000	$0.25	Anytime	5-Apr-14
	Warrants exercised on February 25, 2013	(200,000)	$0.25
	Warrants exercised on February 28, 2013	-200,000	$0.25
	Warrants exercised on March 22, 2013	(200,000)	$0.25
	Warrants exercised on March 27, 2013	-600,000	$0.25
	Warrants exercised on May 22, 2013	-200,000	$0.25
	Warrants expired on April 10, 2013	-600,000	$0.25
	Warrants expired on April 15, 2013	-100,000	$0.25
	Warrants expired on April 5, 2014	-500,000	$0.25
	Warrants outstanding as at June 30, 2014	-	$      -

Income_Taxes

Income Taxes	6 Months Ended
	Jun. 30, 2014
Notes	'
Income Taxes	'
	8.       INCOME TAXES
	The Company accounts for income taxes in accordance with ASC 740-20. ASC 740-20 prescribes the use of the liability method whereby deferred tax asset and liability account balances are determined based on differences between the financial reporting and tax basis of assets and liabilities and are measured using the enacted tax rates. The effects of future changes in tax laws or rates are not anticipated.
	Under ASC 740-20 income taxes are recognized for the following: a) amount of tax payable for the current year, and b) deferred tax liabilities and assets for future tax consequences of events that have been recognized differently in the financial statements than for tax purposes.
	The Company has a Delaware subsidiary which pays an asset-based tax.  Tax expense in the current year relate to asset based taxes on the Company’s Delaware subsidiary. Other than the Delaware subsidiary, the Company pays taxes based on income. The Company has income tax losses available to be applied against future year’s income as a result of the losses incurred since inception. However, due to the losses incurred since inception and expected future operating results, management determined that it is more likely than not that the deferred tax asset resulting from the tax losses available for carry forward will not be realized through the reduction of future income tax payments. Accordingly a 100% valuation allowance has been recorded for income tax losses available for carry forward.
	As of June 30, 2014, the Company did not have any amounts recorded pertaining to uncertain tax positions.  The Company files federal and provincial income tax returns in Canada and federal, state and local income tax returns in the U.S., as applicable.  The Company may be subject to a reassessment of federal and provincial income taxes by Canadian tax authorities for a period of three to five years from the date of the original notice of assessment in respect of any particular taxation year.  In certain circumstances, the U.S. federal statute of limitations can reach beyond the standard three year period.  U.S. state statutes of limitations for income tax assessment vary from state to state.

Property_and_Equipment

Property and Equipment	6 Months Ended
	Jun. 30, 2014
Notes	'
Property and Equipment	'
	9.                PROPERTY AND EQUIPMENT
		As at June 30, 2014
		Cost	Accumulated Depreciation	Net Book Value
	Leasehold improvements	$   84,816	$     33,906	$    50,910
	Furniture & Equipment	28,652	7,191	21,461
	Lab Equipment	14,448	4,916	9,532
	Computer equipment	1,820	1,212	608
		$129,736	$   47,225	$    82,511
		As at December 31, 2013
		Cost	Accumulated Depreciation	Net Book Value
	Leasehold improvements	$   79,866	$     28,516	$      51,350
	Furniture & Equipment	20,001	5,659	14,342
	Lab Equipment	14,448	2,628	11,820
	Computer equipment	1,820	1,096	724
		$116,135	$    37,899	$    78,236
	During the year, the Company began acquiring and using property and equipment which were depreciated accordingly.

Equity_Compensation

Equity Compensation	6 Months Ended
	Jun. 30, 2014
Notes	'
Equity Compensation	'
	10.             EQUITY COMPENSATION
	On April 10, 2014, the Company granted 1,300,000 options to officers, directors and consultants of the Company as incentive compensation. The options vested and became exercisable on April 10, 2014 at an exercise price of $0.55 per share and expire on April 10, 2016.
	Stock based compensation of $802,800 was expensed in the financial statements during the three and six months ended June 30, 2014 ($- during the three and six months ended June 30, 2013) relating to current period grants.
	The fair value of each option granted was estimated on the date of the grant using the Black-Scholes fair value option pricing model with the following assumptions: fair value of options of $0.62, risk-free rate of 0.37%, expected life of the options of two years, annualized volatility of 242%, and no expected dividends. Volatility was determined based on daily observations of the historical stock price over a period consistent with the expected life of the options at the date of grant.
	The following table provides consolidated summary information on the Company’s equity compensation plans as at June 30, 2014.
		Number of  Options	Exercise Price	Fair Value Per Option	Expiry Date
	Options outstanding as at December 31, 2013	4,500,000	$0.55	0.25	26-Jul-21
	Options issued on April 10, 2014	1,300,000	$0.55	0.62	10-Apr-16
	Options outstanding as at June 30, 2014	5,800,000	$0.55
	As of June 30, 2014, there was no unrecognized compensation related to non-vested options.

Related_Party_Transactions

Related Party Transactions	6 Months Ended
	Jun. 30, 2014
Notes	'
Related Party Transactions	'
	11.             RELATED PARTY TRANSACTIONS
	During the year, the Company paid back amounts due to related parties, which had been advanced in the past to fund its operating and investing activities.  Amounts due to related parties are due on demand, are non-interest bearing and approximate fair value due to their short term to maturity. Amounts due from Dr. Moshiri, CEO, relate to advances for business related travel and are short-term in nature. Amounts due from Dr. Stead relate to advances for product-related research costs. Amounts due to related parties as at June 30, 2014 and December 31, 2013 are as follows:
		30-Jun-14	31-Dec-13
	Due to (from) Dr. Moshiri, CEO of the Company	$      (55,428)	$           2,256
	Due to (from) Dr. Ronald H. Stead	-65,569	-
	Due to a company controlled by a shareholder of the Company	661,807	717,953
	Total	$540,810	$720,209

Lease_Commitments

Lease Commitments	6 Months Ended
	Jun. 30, 2014
Notes	'
Lease Commitments	'
	12.    LEASE COMMITMENTS
	In 2011, the Company entered into lease for premise in Toronto, Ontario.  The lease term is for 60 months. Rent expense under all operating leases (exclusive of real estate taxes and other expenses payable under the leases) was approximately $34,820 and $15,962 for the six months ended June 30, 2014 and 2013 respectively.
	In addition, the Company is required to pay its pro rata share of common area maintenance costs and property taxes.

Summary_of_Significant_Account1

Summary of Significant Accounting Policies: Basis of Consolidation and Presentation (Policies)	6 Months Ended
	Jun. 30, 2014
Policies	'
Basis of Consolidation and Presentation	'
	Basis of Consolidation and Presentation
	The accompanying interim condensed consolidated financial statements include the accounts of the Company, and its wholly-owned subsidiary Panacea (a Delaware incorporated Company) and Panacea Global Inc. (a Canadian incorporated Company).  All inter-company transactions and balances have been eliminated upon consolidation.
	The interim condensed consolidated financial statements of the Company included herein have been prepared by the Company, without audit, pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”). Certain information and footnote disclosures normally included in financial statements prepared in conjunction with accounting principles generally accepted in the United States have been condensed or omitted pursuant to such rules and regulations, although the Company believes that the disclosures are adequate to make the information presented not misleading. These interim condensed consolidated financial statements should be read in conjunction with the Company’s 2013 year end annual consolidated audited financial statements and the notes thereto included in the Company’s annual report on Form 10-K.
	The accompanying interim condensed consolidated financial statements reflect all adjustments of a normal and recurring nature which are, in the opinion of management, necessary to present fairly the financial position, results of operations and cash flows of the Company for the interim periods presented. The results of operations for these periods are not necessarily comparable to, or indicative of, results of any other interim period or for the fiscal year taken as a whole. Certain information that is not required for interim financial reporting purposes has been omitted.

Summary_of_Significant_Account2

Summary of Significant Accounting Policies: Translation of Foreign Currency Financial Statements and Foreign Currency Transactions (Policies)	6 Months Ended
	Jun. 30, 2014
Policies	'
Translation of Foreign Currency Financial Statements and Foreign Currency Transactions	'
	Translation of Foreign Currency Financial Statements and Foreign Currency Transactions
	The functional currency of the Company is Canadian dollars. The functional currency of the Company’s subsidiaries is United States dollars.  The interim condensed financial statements of the Company have been translated into United States dollars by translating balance sheet accounts at year end and period end exchange rates except for non-current assets which are translated at historical exchange rates, and statement of operations accounts at average exchange rates for the periods. Foreign currency translation gains and losses are reflected in the equity section of the Company’s consolidated balance sheet in Accumulated Other Comprehensive Income (Loss). The balance of the foreign currency translation adjustment, included in Accumulated Other Comprehensive Loss, was $ (103,543) for the six months ended June 30, 2014. For the period from inception (February 5, 2010) through June 30, 2014, $29,663 foreign currency translation adjustment was included in Accumulated Other Comprehensive Income (Loss).

Summary_of_Significant_Account3

Summary of Significant Accounting Policies: Earnings Or Loss Per Share (Policies)	6 Months Ended
	Jun. 30, 2014
Policies	'
Earnings Or Loss Per Share	'
	Earnings or Loss Per Share
	The Company accounts for earnings per share pursuant to ASC 260-10-05, Earnings per Share, which requires disclosure on the financial statements of "basic" and "diluted" earnings (loss) per share. Basic earnings (loss) per share are computed by dividing net income (loss) by the weighted average number of common stock outstanding for the period. Diluted earnings (loss) per share is computed by dividing net income (loss) by the weighted average number of common stock outstanding plus common stock equivalents (if dilutive) related to stock options and warrants for each period.  In periods of losses, diluted loss per share is computed on the same basis as basic loss per share as the inclusion of any other potential shares outstanding would be anti-dilutive.

Summary_of_Significant_Account4

Summary of Significant Accounting Policies: Financial Instruments (Policies)	6 Months Ended
	Jun. 30, 2014
Policies	'
Financial Instruments	'
	Financial Instruments
	In accordance with ASC 825-10-50, Defining Fair Value Measurement, the estimated fair value of financial instruments has been determined by the Company using available market information and valuation methodologies. Considerable judgment is required in estimating fair value. Accordingly, the estimates may not be indicative of the amounts the Company could realize in a current market exchange. As of June 30, 2014, the carrying value of accounts payable and accrued liabilities, due to related parties and license fee payable approximate their fair value because of the short-term maturity of these instruments.  The fair value of the investment is not readily determinable.
	In accordance with ASC 820-10, Defining Fair Value Measurement, the Company adopted the standard which defines fair value, establishes a framework for measuring fair value in generally accepted accounting principles and expands disclosures about fair value measurements.

Summary_of_Significant_Account5

Summary of Significant Accounting Policies: Income Taxes (Policies)	6 Months Ended
	Jun. 30, 2014
Policies	'
Income Taxes	'
	Income Taxes
	The Company accounts for income taxes pursuant to ASC 740-10, Accounting for Income Taxes. Deferred tax assets and liabilities are recorded for differences between the financial statements and tax basis of the assets and liabilities as well as loss carry forward that will result in taxable or deductible amounts in the future based on enacted tax laws and rates. Valuation allowances are established when necessary to reduce deferred tax assets to the amount expected to be realized. Income tax expense is recorded for the amount of income tax payable or refundable for the period increased or decreased by the change in deferred tax assets and liabilities during the period.

Summary_of_Significant_Account6

Summary of Significant Accounting Policies: Impairment of Long-lived Assets (Policies)	6 Months Ended
	Jun. 30, 2014
Policies	'
Impairment of Long-lived Assets	'
	Impairment of Long-lived Assets
	In accordance with ASC 360-10-05, Accounting for the Impairment or Disposal of Long-Lived Assets, long-lived assets to be held and used are analyzed for impairment whenever events or changes in circumstances indicate that the related carrying amounts may not be recoverable. The Company evaluates whether events and circumstances have occurred that indicate possible impairment. If there are indications of impairment, the Company uses future undiscounted cash flows of the related asset or asset grouping over the remaining life in measuring whether the assets are recoverable. In the event such cash flows are not expected to be sufficient to recover the recorded asset values, the assets are written down to their estimated fair value. Long-lived assets to be disposed of are reported at the lower of carrying amount or fair value of asset less cost to sell. The Company evaluated the Global Diagnostic License on June 30, 2014 and noted no impairment.

Summary_of_Significant_Account7

Summary of Significant Accounting Policies: Use of Estimates (Policies)	6 Months Ended
	Jun. 30, 2014
Policies	'
Use of Estimates	'
	Use of Estimates
	The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. These estimates are reviewed periodically, and, as adjustments become necessary, they are reported in earnings in the period in which they become known. The accounting estimates that require management’s most significant judgments are the valuation of the intangible asset and measurement of accrued liabilities.

Summary_of_Significant_Account8

Summary of Significant Accounting Policies: Cash and Cash Equivalents (Policies)	6 Months Ended
	Jun. 30, 2014
Policies	'
Cash and Cash Equivalents	'
	Cash and Cash Equivalents
	For the purposes of the balance sheets and statement of cash flows, cash and cash equivalents include deposits, certificates of deposit and all highly liquid debt instruments with original maturities of three months or less.  The Company maintains cash and cash equivalents at financial institutions which periodically may exceed federally insured limits.

Summary_of_Significant_Account9

Summary of Significant Accounting Policies: Property and Equipment (Policies)	6 Months Ended
	Jun. 30, 2014
Policies	'
Property and Equipment	'
	Property and Equipment
	Property and equipment are initially recorded at cost.  Depreciation is provided using the declining balance method at rates intended to amortize the cost of assets over their estimated useful lives.
		Method	Rate
	Computer equipment	Declining balance	30%
	Furniture and equipment	Declining balance	20%
	Lab equipment	Declining balance	30%
	Leasehold improvements	Declining balance	20%
	In the year of acquisition, depreciation is taken as assets are available for use.

Recovered_Sheet1

Summary of Significant Accounting Policies: Equity Compensation (Policies)	6 Months Ended
	Jun. 30, 2014
Policies	'
Equity Compensation	'
	Equity Compensation
	The Company adopted ASC 718, Share-Based Payment, which establishes standards for transactions in which an entity exchanges its equity instruments for goods and services. This standard focuses primarily on accounting for transactions in which an entity obtains employee services in share-based payment transactions, including issuance of stock options to employees. The Company measures stock-based compensation cost at grant date, based on the estimated fair value of the award, and recognizes the cost as expense on a straight-line basis (net of estimated forfeitures) over the employee requisite service period. The Company estimates the fair value of stock options using a Black-Scholes valuation model.

Recovered_Sheet2

Summary of Significant Accounting Policies: Investment in Equity Instruments (Policies)	6 Months Ended
	Jun. 30, 2014
Policies	'
Investment in Equity Instruments	'
	Investment in Equity Instruments
	The Company has accounted for its investment in equity and debt securities using the equity method of accounting based on the guidelines established in FASB ASC 323. In applying the guidance of FASB ASC 323, the Company recognizes the investment in stock of an investee as an asset. The asset is recorded initially at cost in accordance with the guidance in FASB ASC 805-50-30. Subsequent to the initial recording the Company will recognize its share of the earnings or losses of an investee in the periods for which they are reported by the investee in its financial statements. The Company adjusts the carrying value of the investment for its share of the earnings or losses of the investee after the date of investment and shall report the recognized earnings or losses in the condensed statement of comprehensive loss.

Recovered_Sheet3

Summary of Significant Accounting Policies: Recent Accounting Pronouncements (Policies)	6 Months Ended
	Jun. 30, 2014
Policies	'
Recent Accounting Pronouncements	'
	Recent Accounting Pronouncements
	Changes to accounting principles generally accepted in the United States of America (U.S. GAAP) are established by the Financial Accounting Standards Board (FASB) in the form of accounting standards updates (ASU’s) to the FASB’s Accounting Standards Codification.
	The Company has assessed the applicability and impact of all ASU’S and they have been determined to be either not applicable or are expected to have minimal impact on the Company’s condensed consolidated financial position and statements of operations.

Global_Diagnostic_License_Sche

Global Diagnostic License: Schedule of Cost Method Investments (Tables)	6 Months Ended
	Jun. 30, 2014
Tables/Schedules	'
Schedule of Cost Method Investments	'
	Investment in Laboratories
	November 18, 2011 (initial value)	$	1,000,000
	Share of losses up to December 31, 2013		-88,328
	31-Dec-13		911,672
	Share of loss for the six months ended June 30, 2014		-1,680
	Total	$	909,992

Intangible_Asset_Schedule_of_I

Intangible Asset: Schedule of Intangible Assets and Goodwill (Tables)	6 Months Ended
	Jun. 30, 2014
Tables/Schedules	'
Schedule of Intangible Assets and Goodwill	'
		As at February 5, 2010 (inception)	Acquired	Accumulated Amortization	As at December 31, 2013	Accumulated Amortization	As at
							30-Jun-14
	Global Diagnostic License	-	$50,000,000	-	$50,000,000	-	$50,000,000

Capital_Stock_Schedule_of_Stoc

Capital Stock: Schedule of Stockholders Equity (Tables)	6 Months Ended
	Jun. 30, 2014
Tables/Schedules	'
Schedule of Stockholders Equity	'
		Number of Shares	Capital Stock	Additional
				paid in capital
	Capital stock as at December 31, 2011	94,063,586	94,064	49,869,603
	Stock issuances in 2012	1,300,000	1,300	519,814
	Capital stock as at December 31, 2012	95,363,586	$95,364	$50,389,417
	Stock issuance in 2013	10,634,000	10,634	4,756,366
	Capital stock as at December 31, 2013	105,997,586	$105,998	$55,145,783
	Stock based compensation in 2014	-	-	802,800
	Capital stock as at June 30, 2014	105,997,586	$105,998	$55,948,583

Capital_Stock_Schedule_of_Stoc1

Capital Stock: Schedule of Stockholders' Equity Note, Warrants or Rights (Tables)	6 Months Ended
	Jun. 30, 2014
Tables/Schedules	'
Schedule of Stockholders' Equity Note, Warrants or Rights	'
		Number of  Warrants	Exercise Price	Exercisable Date	Expiry Date
	Warrants issued on April 10, 2011	2,000,000	$0.25	Anytime	10-Apr-13
	Warrants issued on April 15, 2011	100,000	$0.25	Anytime	15-Apr-13
	Warrants issued on April 5, 2012	500,000	$0.25	Anytime	5-Apr-14
	Warrants exercised on February 25, 2013	(200,000)	$0.25
	Warrants exercised on February 28, 2013	-200,000	$0.25
	Warrants exercised on March 22, 2013	(200,000)	$0.25
	Warrants exercised on March 27, 2013	-600,000	$0.25
	Warrants exercised on May 22, 2013	-200,000	$0.25
	Warrants expired on April 10, 2013	-600,000	$0.25
	Warrants expired on April 15, 2013	-100,000	$0.25
	Warrants expired on April 5, 2014	-500,000	$0.25
	Warrants outstanding as at June 30, 2014	-	$      -

Property_and_Equipment_Propert

Property and Equipment: Property and Equipment Tables (Tables)	6 Months Ended
	Jun. 30, 2014
Tables/Schedules	'
Property and Equipment Tables	'
		As at June 30, 2014
		Cost	Accumulated Depreciation	Net Book Value
	Leasehold improvements	$   84,816	$     33,906	$    50,910
	Furniture & Equipment	28,652	7,191	21,461
	Lab Equipment	14,448	4,916	9,532
	Computer equipment	1,820	1,212	608
		$129,736	$   47,225	$    82,511
		As at December 31, 2013
		Cost	Accumulated Depreciation	Net Book Value
	Leasehold improvements	$   79,866	$     28,516	$      51,350
	Furniture & Equipment	20,001	5,659	14,342
	Lab Equipment	14,448	2,628	11,820
	Computer equipment	1,820	1,096	724
		$116,135	$    37,899	$    78,236

Equity_Compensation_Schedule_o

Equity Compensation: Schedule of Share-based Compensation, Activity (Tables)	6 Months Ended
	Jun. 30, 2014
Tables/Schedules	'
Schedule of Share-based Compensation, Activity	'
		Number of  Options	Exercise Price	Fair Value Per Option	Expiry Date
	Options outstanding as at December 31, 2013	4,500,000	$0.55	0.25	26-Jul-21
	Options issued on April 10, 2014	1,300,000	$0.55	0.62	10-Apr-16
	Options outstanding as at June 30, 2014	5,800,000	$0.55

Going_Concern_Details

Going Concern (Details) (USD $)	Jun. 30, 2014	Dec. 31, 2013
Details	'	'
Deficit accumulated during the development stage	$6,649,972	$4,720,970

Recovered_Sheet4

Summary of Significant Accounting Policies: Translation of Foreign Currency Financial Statements and Foreign Currency Transactions (Details) (USD $)	53 Months Ended
	Jun. 30, 2014
Details	'
Accumulated Other Comprehensive Income (Loss), before Tax	($103,543)
Foreign currency exchange adjustment	$29,663

Global_Diagnostic_License_Deta

Global Diagnostic License (Details) (USD $)

3 Months Ended

6 Months Ended

36 Months Ended

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2013

Nov. 30, 2014

Dec. 31, 2013

Dec. 04, 2013

Aug. 13, 2013

Jul. 26, 2013

Jul. 08, 2013

Jun. 04, 2013

31-May-13

Apr. 29, 2013

Mar. 01, 2013

Oct. 12, 2012

Sep. 25, 2012

Sep. 17, 2012

Aug. 17, 2012

Apr. 05, 2012

Dec. 31, 2011

Mar. 24, 2010

Details

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common Stock, Shares Issued

105,997,586

105,997,586

'

'

105,997,586

50,000

100,000

100,000

680,000

20,000

860,000

1,184,000

40,000

100,000

320,000

280,000

100,000

500,000

'

35,500,000

License Fee

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$2,500,000

License Fee Payable

2,220

64,976

323,444

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

License Payment

639,187

639,187

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Balance Receivable

64,976

64,976

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Sublicense Agreement

'

'

'

40,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Sublicense Fee

'

'

'

960,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Sublicensing Revenue

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$1,000,000

'

Global_Diagnostic_License_Sche1

Global Diagnostic License: Schedule of Cost Method Investments (Details) (USD $)	6 Months Ended		25 Months Ended	53 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Dec. 31, 2013	Jun. 30, 2014	Nov. 18, 2011
Details	'	'	'	'	'
Investment, Initial Value	'	'	'	'	$1,000,000
Total Income (Loss)	1,115,786	500,538	-88,328	4,527,261	'
Total Operating Loss	'	'	911,672	'	'
Other Operating Income	($1,680)	'	'	'	'

Intangible_Asset_Schedule_of_I1

Intangible Asset: Schedule of Intangible Assets and Goodwill (Details) (USD $)	Jun. 30, 2014	Dec. 31, 2013	Feb. 06, 2010
Details	'	'	'
Other Intangible Assets, Net	$50,000,000	$50,000,000	'
License Acquired	'	'	$50,000,000

Capital_Stock_Details

Capital Stock (Details) (USD $)

Jun. 30, 2014

Dec. 31, 2013

Dec. 04, 2013

Aug. 13, 2013

Jul. 26, 2013

Jul. 08, 2013

Jun. 04, 2013

31-May-13

Apr. 29, 2013

Mar. 01, 2013

Oct. 12, 2012

Sep. 25, 2012

Sep. 17, 2012

Aug. 17, 2012

Apr. 05, 2012

Mar. 24, 2010

Feb. 25, 2013

Warrants

Authorized Preferred Class A Shares

100,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Authorized Preferred Class A Par Value

$0.00

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common Stock, Shares Authorized

300,000,000

300,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common Stock, Par Value

$0.00

$0.00

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common Stock, Shares Issued

105,997,586

105,997,586

50,000

100,000

100,000

680,000

20,000

860,000

1,184,000

40,000

100,000

320,000

280,000

100,000

500,000

35,500,000

1,600,000

Issuance of Common Stock for Cash

'

$3,000,000

$25,000

$50,000

$50,000

$287,105

$10,000

$380,000

$592,000

$20,000

$50,000

$160,000

$139,477

$49,985

$121,652

'

$352,895

Balance, Shares

'

6,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Capital_Stock_Schedule_of_Stoc2

Capital Stock: Schedule of Stockholders Equity (Details) (USD $)	3 Months Ended	6 Months Ended	53 Months Ended
	Jun. 30, 2014	Jun. 30, 2014	Jun. 30, 2014	Dec. 31, 2013	Dec. 31, 2012
Details	'	'	'	'	'
Capital Stock	105,997,586	105,997,586	105,997,586	105,997,586	95,363,586
Capital Stock Amount	$105,998	$105,998	$105,998	$105,998	$95,364
Additional Paid in Capital, Common Stock	55,948,583	55,948,583	55,948,583	55,145,783	50,389,417
Stock Issuances, Number of Shares	'	'	'	10,634,000	1,300,000
Stock Issuances, Amount	'	'	'	10,634	1,300
Additional Paid In Capital, Stock Issuances.	'	'	'	4,756,366	519,814
Stock based compensation	$802,800	$802,800	$1,927,167	'	'

Capital_Stock_Schedule_of_Stoc3

Capital Stock: Schedule of Stockholders' Equity Note, Warrants or Rights (Details) (USD $)	24 Months Ended
	Apr. 05, 2014	Apr. 15, 2013	Apr. 10, 2013	22-May-13	Mar. 27, 2013	Mar. 22, 2013	Feb. 28, 2013	Feb. 25, 2013	Apr. 05, 2012	Apr. 15, 2011	Apr. 10, 2011
Details	'	'	'	'	'	'	'	'	'	'	'
Warrants Issued	'	'	'	'	'	'	'	'	500,000	100,000	2,000,000
Class of Warrant or Right, Exercise Price of Warrants or Rights	$0.25	$0.25	$0.25	$0.25	$0.25	$0.25	$0.25	$0.25	$0.25	$0.25	$0.25
Investment Warrants Expiration Date	5-Apr-14	15-Apr-13	10-Apr-13	'	'	'	'	'	'	'	'
Warrants Exercised	'	'	'	-200,000	-600,000	-200,000	-200,000	-200,000	'	'	'
Warrants Expired	-500,000	-100,000	-600,000	'	'	'	'	'	'	'	'

Property_and_Equipment_Propert1

Property and Equipment: Property and Equipment Tables (Details) (USD $)	Jun. 30, 2014	Dec. 31, 2013
Leasehold Improvements	'	'
Deferred Costs, Noncurrent	$84,816	$79,866
Property, Plant and Equipment, Other, Accumulated Depreciation	33,906	28,516
Net Book Value	50,910	51,350
Furniture and Equipment	'	'
Deferred Costs, Noncurrent	28,652	20,001
Property, Plant and Equipment, Other, Accumulated Depreciation	7,191	5,659
Net Book Value	21,461	14,342
Lab Equipment	'	'
Deferred Costs, Noncurrent	14,448	14,448
Property, Plant and Equipment, Other, Accumulated Depreciation	4,916	2,628
Net Book Value	9,532	11,820
Computer Equipment	'	'
Deferred Costs, Noncurrent	1,820	1,820
Property, Plant and Equipment, Other, Accumulated Depreciation	1,212	1,096
Net Book Value	$608	$724

Equity_Compensation_Details

Equity Compensation (Details) (USD $)	0 Months Ended	3 Months Ended	4 Months Ended	6 Months Ended	12 Months Ended	53 Months Ended
	Apr. 10, 2014	Jun. 30, 2014	Apr. 30, 2014	Jun. 30, 2014	Dec. 31, 2013	Jun. 30, 2014
Details	'	'	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures	1,300,000	'	'	'	'	'
Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price	$0.55	'	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Date	10-Apr-16	'	10-Apr-16	'	26-Jul-21	'
Stock based compensation	'	$802,800	'	$802,800	'	$1,927,167
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value	'	$0.62	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate	'	0.37%	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate	'	242.00%	'	'	'	'

Equity_Compensation_Schedule_o1

Equity Compensation: Schedule of Share-based Compensation, Activity (Details) (USD $)	0 Months Ended	4 Months Ended	12 Months Ended
	Apr. 10, 2014	Apr. 30, 2014	Dec. 31, 2013	Jun. 30, 2014
Details	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number	'	'	4,500,000	5,800,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price	'	'	$0.55	$0.55
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Exercise Price	'	'	$0.25	$0.62
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Date	10-Apr-16	10-Apr-16	26-Jul-21	'
Options Issued	1,300,000	'	'	'
Options Exercise Price	$0.55	'	'	'

Related_Party_Transactions_Det

Related Party Transactions (Details) (USD $)	Dec. 31, 2103	Jun. 30, 2014
Dr. Moshiri CEO	'	'
Related Party Transaction, Due from (to) Related Party	($2,256)	($55,428)
Related Party Transaction, Due from (to) Related Party	2,256	55,428
Dr. Ronald H. Stead	'	'
Related Party Transaction, Due from (to) Related Party	'	-65,569
Related Party Transaction, Due from (to) Related Party	'	65,569
Company Controlled By Shareholder Of Company	'	'
Related Party Transaction, Due from (to) Related Party	-717,953	-661,807
Related Party Transaction, Due from (to) Related Party	717,953	661,807
Total	'	'
Related Party Transaction, Due from (to) Related Party	-720,209	-540,810
Related Party Transaction, Due from (to) Related Party	$720,209	$540,810

Lease_Commitments_Details

Lease Commitments (Details) (USD $)	6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013
Details	'	'
Operating Leases, Rent Expense	$34,820	$15,962